Search results for "amine"

showing 10 items of 7299 documents

The short‐term effect of levocetirizine on quality of life, stress, and depression in itchy psoriasis patients

2019

AdultHistamine H1 Antagonists Non-Sedatingmedicine.medical_specialtyMEDLINEDermatologyLevocetirizineQuality of life (healthcare)Surveys and QuestionnairesInternal medicinePsoriasisHumansPsoriasisMedicineTerm effectDepression (differential diagnoses)Depressionbusiness.industryPruritusGeneral MedicineMiddle AgedHistamine H1 Antagonistsmedicine.diseaseCetirizineQuality of LifebusinessStress Psychologicalmedicine.drugDermatologic Therapy
researchProduct

Identification and expansion of human osteosarcoma-cancer-stem cells by long-term 3-aminobenzamide treatment

2009

A novel cancer stem-like cell line (3AB-OS), expressing a number of pluripotent stem cell markers, was irreversibly selected from human osteosarcoma MG-63 cells by long-term treatment (100 days) with 3-aminobenzamide (3AB). 3AB-OS cells are a heterogeneous and stable cell population composed by three types of fibroblastoid cells, spindle-shaped, polygonal-shaped, and rounded-shaped. With respect to MG-63 cells, 3AB-OS cells are extremely smaller, possess a much greater capacity to form spheres, a stronger self-renewal ability and much higher levels of cell cycle markers which account for G1-S/G2-M phases progression. Differently from MG-63 cells, 3AB-OS cells can be reseeded unlimitedly wit…

AdultHomeobox protein NANOGAdolescentPhysiologyCellular differentiationClinical BiochemistryApoptosisBiologyStem cell markerYoung Adultcancer stemm cells osteosarcoma PARP inhibitorsCancer stem cellCell Line TumorSettore BIO/10 - BiochimicaHumansRhodamine 123Enzyme InhibitorsProgenitor cellChildInduced pluripotent stem cellCell ShapeCell potencyFluorescent DyesOsteosarcomaCell DifferentiationCell BiologyCalcium Channel BlockersDrug Resistance MultipleGene Expression Regulation NeoplasticVerapamilBenzamidesImmunologyNeoplastic Stem CellsCancer researchATP-Binding Cassette TransportersBenzimidazolesStem cellBiomarkersJournal of Cellular Physiology
researchProduct

Adverse effects associated with the short-term treatment of panic disorder with imipramine, alprazolam or placebo

1994

Summary Side effects play a significant role in the selection of drugs to be used in panic disorder/agoraphobia whose polyphobic symptomatology often includes a suspiciousness about taking drugs and a fear of undesired side effects which may lead to the refusal of treatment. The safety, side effects and patients' acceptance of alprazolam and imipramine versus placebo were evaluated in 1168 subjects with panic disorder/agoraphobia who had been enrolled in the second phase of the Upjohn World Wide Panic Study. Side effects that worsened over baseline to a greater extent with alprazolam than with imipramine and placebo were sedation, fatigue/weakness, memory problems, ataxia and slurred speech…

AdultImipramineAdolescentSide effectPoison controlPlaceboImipramineDouble-Blind MethodmedicineHumansPharmacology (medical)Biological PsychiatryAgedPsychiatric Status Rating ScalesPharmacologyAlprazolambusiness.industryPanic disorderPanicMiddle Agedmedicine.diseasePsychiatry and Mental healthNeurologyAlprazolamAnesthesiaPanic DisorderPatient ComplianceNeurology (clinical)medicine.symptombusinessAgoraphobiamedicine.drugEuropean Neuropsychopharmacology
researchProduct

Vasopressor and inotrope treatment for septic shock: An umbrella review of reviews

2021

Abstract Purpose To review the characteristics, findings and quality of systematic reviews (SRs) on the effect of any vasopressor/inotrope on outcomes in adult patients with sepsis compared with either no treatment, another vasopressor or inotrope or fluids. Materials and methods We systematically searched Cochrane Central Register of Controlled Trials, PubMed and Embase (January 1993–March 2021). Descriptive statistics were used. Results Among the 28 SRs identified, mortality was the primary outcome in most (26/28) and mortality was usually (23/28) studied using randomised controlled trials (RCTs). Fifteen SRs focused exclusively on patients with sepsis or septic shock. Sepsis and septic s…

AdultInotropemedicine.medical_specialtyBlindingmedia_common.quotation_subjectReviewCritical Care and Intensive Care MedicineNorepinephrine (medication)SepsisNorepinephrine03 medical and health sciencesCatecholamines0302 clinical medicineSepsisparasitic diseasesmedicineHumansMulticenter Studies as TopicVasoconstrictor Agentsmedia_commonSelection biasSeptic shockbusiness.industry030208 emergency & critical care medicinePublication biasmedicine.diseaseShock SepticSystematic review030228 respiratory systemEmergency medicinebusinessCardiotonic agentsSystematic Reviews as Topicmedicine.drugJournal of Critical Care
researchProduct

Frequent Alteration of the Yin Yang 1/Raf-1 Kinase Inhibitory Protein Ratio in Hepatocellular Carcinoma

2011

The transcription factor Yin Yang 1 (YY1) can favor several aspects of tumorigenesis. In turn, Raf-1 Kinase Inhibitor Protein (RKIP) inhibits the oncogenic activities of MAPK and NF-κB pathways and promotes drug-induced apoptosis. Mutual influences between YY1 and RKIP may exist, and there are already separate evidences that relevant increases in YY1 and reductions in RKIP occur in hepatocellular carcinoma (HCC). However, the levels of the two factors have never been concomitantly examined in HCC. We evaluated by RT-PCR the mRNA levels of YY1, YY1AP, RKIP, and survivin in 35 clinical HCCs (91% HCV-related), in their adjacent cirrhotic tissues and in 6 healthy livers. Immunohistochemical ana…

AdultLiver CirrhosisMaleMAPK/ERK pathwayCarcinoma HepatocellularSettore MED/09 - Medicina InternaSurvivinCell Cycle ProteinsPhosphatidylethanolamine Binding ProteinSettore MED/08 - Anatomia PatologicaBiologymedicine.disease_causeBiochemistryInhibitor of Apoptosis ProteinsSurvivinGeneticsmedicineHumansRNA MessengerHepatocellular carcinomaYY1RKIPMolecular BiologyTranscription factorYY1 Transcription FactorAgedAged 80 and overSettore MED/12 - GastroenterologiaHepatocellular carcinoma Yin Yang 1 Raf-1 Kinase Inhibitor Protein Yin Yang 1-associated proteinKinaseYY1Liver NeoplasmsNuclear ProteinsMiddle AgedHCCSmedicine.diseaseGene Expression Regulation NeoplasticLiverHepatocellular carcinomaembryonic structuresSettore BIO/14 - FarmacologiaCancer researchMolecular MedicineFemaleSettore SECS-S/01 - StatisticaCarcinogenesisTranscription FactorsBiotechnologyOMICS: A Journal of Integrative Biology
researchProduct

Anti-tissue transglutaminase antibodies in patients with abnormal liver tests: is it always coeliac disease?

2005

Coeliac disease (CD) is found in 5-10% of patients with chronically abnormal liver tests and no obvious cause of liver disease. In this population the efficacy of screening for CD by anti-tissue transglutaminase (anti-tTG) may be impaired by the high rate of positive anti-tTG found in chronic liver disease.To evaluate the prevalence of coeliac disease and the role of anti-tTG in patients with non-viral, non-autoimmune chronic and no obvious cause of liver damage.Out of 2,512 consecutive patients with abnormal liver tests, 168 (118 men, 50 women; mean age 40.7 +/- 12.6 years) were defined, on the basis of clinical data and liver biopsy, as NAFLD or cryptogenic chronic hepatitis. All were tes…

AdultLiver CirrhosisMalePathologymedicine.medical_specialtyAdolescentTissue transglutaminaseDuodenumBiopsyGastroenterologyCoeliac diseaseGTP-Binding ProteinsInternal medicineBiopsymedicineHumansMass ScreeningIn patientProtein Glutamine gamma Glutamyltransferase 2Aspartate AminotransferasesDuodenoscopyMass screeningAgedAutoantibodiesHepatitis ChronicHepatitisTransglutaminasesHepatologybiologymedicine.diagnostic_testbusiness.industryLiver DiseasesGastroenterologynutritional and metabolic diseasesAlanine TransaminaseMiddle Agedmedicine.diseasedigestive system diseasesImmunoglobulin AFatty LiverCeliac DiseaseLiverImmunoglobulin Gbiology.proteinFemaleAbnormal liverAntibodybusinessThe American journal of gastroenterology
researchProduct

Correlation of nitric oxide and atrial natriuretic peptide changes with altered cGMP homeostasis in liver cirrhosis.

2005

: Background: Cyclic GMP (cGMP) concentration is increased in plasma of patients with liver cirrhosis. Three possible mechanisms may contribute: increased cGMP synthesis by soluble (activated by nitric oxide), or particulate (activated by atrial natriuretic peptide (ANP)) guanylate cyclase or increased release from cells. Aim: The aim of this work was to analyze the possible contributors to increased plasma cGMP and to assess whether changes in the parameters of the system vary with the degree of liver disease (Child Pugh score) or by the presence of ascites. Methods: We measured cGMP in plasma and lymphocytes, soluble guanylate cyclase activation by nitric oxide in lymphocytes, nitrates an…

AdultLiver CirrhosisMalemedicine.medical_specialtyGUCY1B3Nitric OxideNitric oxidechemistry.chemical_compoundAtrial natriuretic peptideInternal medicinemedicineHumansLymphocytesCyclic GMPCells CulturedNitritesAgedNitratesHepatologyPenicillamineGUCY1A3AscitesMiddle AgedNPR1PDE5 drug designEndocrinologychemistryGuanylate CyclaseCGMP transportAtrial Natriuretic FactorHomeostasisLiver International
researchProduct

Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial.

2002

Deferiprone has been suggested as an effective oral chelation therapy for thalassemia major. To assess its clinical efficacy, we compared deferiprone with deferoxamine in a large multicenter randomized clinical trial. One-hundred forty-four consecutive patients with thalassemia major and serum ferritin between 1500 and 3000 ng/ml were randomly assigned to deferiprone (75 mg/kg/day) (n = 71) or deferoxamine (50 mg/kg/day) (n = 73) for 1 year. The main measure of efficacy was the reduction of serum ferritin. Liver and heart iron contents were assessed by magnetic resonance. Liver iron content and fibrosis stage variations were assessed on liver biopsy by the Ishak score in all patients willin…

AdultLiver CirrhosisMalemedicine.medical_specialtyIron OverloadAdolescentPyridonesThalassemiaDeferoxamineIron Chelating AgentsGastroenterologylaw.inventionchemistry.chemical_compoundLeukocytopeniaRandomized controlled triallawInternal medicinemedicineHumansDeferiproneChelation therapyMolecular Biologymedicine.diagnostic_testbusiness.industrybeta-ThalassemiaCell BiologyHematologymedicine.diseaseIshak ScoreSurgeryDeferoxamineTreatment OutcomechemistryTherapeutic EquivalencyLiver biopsyFerritinsMolecular MedicineFemaleDeferipronebusinessmedicine.drugBlood cells, moleculesdiseases
researchProduct

The effects of prebiotics on microbial dysbiosis, butyrate production and immunity in HIV-infected subjects

2017

Altered interactions between the gut mucosa and bacteria during HIV infection seem to contribute to chronic immune dysfunction. A deeper understanding of how nutritional interventions could ameliorate gut dysbiosis is needed. Forty-four subjects, including 12 HIV+ viremic untreated (VU) patients, 23 antiretroviral therapy-treated (ART(+)) virally suppressed patients (15 immunological responders and 8 non-responders) and 9 HIV- controls (HIV-), were blindly randomized to receive either prebiotics (scGOS/lcFOS/glutamine) or placebo (34/10) over 6 weeks in this pilot study. We assessed fecal microbiota composition using deep 16S rRNA gene sequencing and several immunological and genetic marker…

AdultMale0301 basic medicine030106 microbiologyImmunologyHIV InfectionsInflammationButyrateBiologyGut floraMicrobiologyFeces03 medical and health sciencesIntestinal mucosaImmunityRNA Ribosomal 16SmedicineHumansImmunology and AllergyIntestinal MucosaBacteriaImmunityMiddle AgedPlacebo Effectmedicine.diseasebiology.organism_classificationGastrointestinal MicrobiomeGlutamineButyratesPrebiotics030104 developmental biologyMucosal immunologyDietary SupplementsHost-Pathogen InteractionsImmunologyHIV-1DysbiosisFemalemedicine.symptomDysbiosisMucosal Immunology
researchProduct

Genotype and allele frequencies of isoniazid-metabolizing enzymes NAT2 and GSTM1 in Latvian tuberculosis patients

2016

Pharmacogenomic testing of tuberculosis drug-metabolizing enzyme genes was proposed as a strategy to identify patients at risk for suboptimal responses to medications. However, variations of the genotype frequencies among ethnic groups exist and new alleles are been identified. The aim of this study was to identify polymorphisms of genes encoding metabolic enzymes NAT2 and GSTM1 in tuberculosis patients in Latvia and to estimate the frequency of NAT2 slow acetylator and GSTM1 null genotypes. In total, 85 DNA samples were genotyped, all individuals were Caucasian. An ethnic heterogeneity reflecting the multiethnic population of the country was observed. 49 patients were Latvians, 30 were Rus…

AdultMale0301 basic medicineMicrobiology (medical)TuberculosisGenotypeArylamine N-AcetyltransferaseAntitubercular AgentsBiologyYoung Adult03 medical and health sciencesGene FrequencyGenotypeIsoniazidmedicineHumansTuberculosisPharmacology (medical)AlleleGenotypingAllele frequencyAgedGlutathione TransferaseGeneticsPolymorphism GeneticIsoniazidMiddle Agedmedicine.diseaseLatviaGenotype frequency030104 developmental biologyInfectious DiseasesFemalePharmacogeneticsmedicine.drugJournal of Infection and Chemotherapy
researchProduct